The pharmaceuticals major was boosted by high demand for its key drugs that offset a slight sales drop in China.

Pharma giant AstraZeneca urged Britain to improve the environment for businesses in order to drive investment, days after it ...

AstraZeneca has been approached a couple of times by Chinese authorities about their investigation into the drugmaker's ...

AstraZeneca has ended development of its oral factor D inhibitor vemircopan, triggering a $753 million impairment charge as ...

Total Revenue is expected to increase by a high single-digit percentage; The Core Tax rate is expected to be between 18-22%. Guidance for FY25 ...

In a report released today, Peter Welford from Jefferies maintained a Hold rating on AstraZeneca (AZN – Research Report), with a price target ...

AstraZeneca said the taxes related to two cancer drugs, Imfinzi and Imjudo, and that it was continuing to co-operate with ...

The AstraZeneca PLC ADR AZN advanced 2.86% to $70.94 Wednesday, on what proved to be an all-around favorable trading session ...

AstraZeneca overcame a drop in sales in China and the arrest of its top executive in the country to deliver an 18 per cent increase in revenues in the final quarter 2024. The London-listed company ...

AstraZeneca Plc reported better-than-expected profit and sales in the fourth quarter and forecast further gains as the UK drugmaker’s blockbuster cancer drugs offset weakened China sales.

CAMBRIDGE, Britain (AP) — CAMBRIDGE, Britain (AP) — Astrazeneca PLC (AZN) on Thursday reported fourth-quarter earnings of $1.5 billion. On a per-share basis, the Cambridge, Britain-based company said ...

The FTSE 100 index is set to make a swift return towards record territory after IG Index futures forecast a rise of 58 points ...